In 2021, the American Academy of Pediatrics, American Academy of Child and Adolescent Psychiatry, and the Children’s Hospital Association jointly declared a national emergency in child and adolescent ...

Several data points for lebrikizumab (EBGLYSS; Lilly), a monoclonal antibody targeting interleukin-13, were reported at the 2025 American Academy of Dermatology (AAD) meeting held in Orlando, Florida ...

A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments. As we transition into the second ...

Our editorial advisory board member Donna Hallas, , PPCNP-BC, CPNP, PMHS, FAANP, FAAN, highlights an article published in the March issue of Contemporary Pediatrics. Many parents may be using at-home ...

Peter S. Jensen, MD, discusses the risks and benefits of social media use by children, emphasizing the need for parental oversight and national guidelines. Social media use among children and ...

A 13-year-old female with a history of iron deficiency anemia presented with altered mental status preceded by 5 days of headache, vomiting, nausea, and worsening somnolence that was not responsive to ...

Recent research detailed that a child was most likely to be killed in a mass shooting by a parent or family member vs a stranger or peer. Study investigator Stephanie Chao, MD, breaks down these data.

The PANDAS/PANS questionnaire is based on symptoms and comorbidities described in the literature and is a self-report completed by parents of children younger than 18. Investigators examined the ...

Take your best guess and try to diagnose this 9-year-old girl's linear eruption on the back of her left thigh and leg. Stay tuned for the full case presentation and correct diagnosis! Welcome to this ...

In the phase 1/2 INSPIRE DUCHENNE trial, data from the first 3 patients dosed revealed an average microdystrophin expression of 110%, as measured by western blot, and improvements in multiple ...

Mesoblast's remestemcel-L (Ryoncil) was approved by the FDA on December 18, 2024 to treat SR-aGVHD in patients 2 months and older. Now, it is available for purchase. The FDA-approved allogeneic (donor ...

A new clinical trial has found that omalizumab (Xolair; Genetech, Novartis) is more effective than oral immunotherapy (OIT) in treating multi-food allergy in individuals with severe allergic reactions ...